Skip to main content
SpringerLink
Log in

Limited-sampling models for anticancer agents

  • Original Papers
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate population pharmacokinetic/pharmacodynamic studies, which eventually may lead to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

LSM:

limited-sampling model

AUC:

area under the concentration/time curve

References

  • Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD (1988) Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol 6:1192–1196

    PubMed  Google Scholar 

  • Adamson PC, Balis FM, Miser J, Arndt C, Wells RJ, Gillespie A, Aronson L, Penta JS, Clendeninn NJ, Poplack DG (1992) Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 52:521–524

    PubMed  Google Scholar 

  • Bennet CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952–1956

    PubMed  Google Scholar 

  • Bressolle F, Ray P, Jacquet JM, Brès J, Galtier M, Donadio D, Jourdan J, Rossi JF (1991) Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother Pharmacol 29:53–60

    PubMed  Google Scholar 

  • Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–56

    PubMed  Google Scholar 

  • CD-ROM MEDLINE (1993) Compact Cambridge, Wisconsin Ave, Bethesda, USA

  • Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73–80

    PubMed  Google Scholar 

  • Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA (1989) Phase I trial empolying adaptive control dosing of hexamethylene bisacetammide (HMBA, NCS 95580). Cancer Res 49:3436–3440

    PubMed  Google Scholar 

  • Cooper MR, Lieberman R, LaRocca RV, Gernt PR, Weinberger RN, Headle RN, Kohler DR, Goldspiel BR, Peck CC, Meyers CE (1992) Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther 52:11–23

    PubMed  Google Scholar 

  • Desai ZR, Van den Berg HW, Bridges JM, Shanks RG (1982) Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8:211–214

    PubMed  Google Scholar 

  • Drusano GL, Forrest A, Snyder MJ, Reed MD Blumer JL (1988) An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 44:232–8

    PubMed  Google Scholar 

  • Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction ofcis-diamine(1,1-cyclobutannedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432–5438

    PubMed  Google Scholar 

  • Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Sigman LM, Enlish KL, Aisner J (1986) Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogoril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46:1513–1520

    PubMed  Google Scholar 

  • Egorin MJ, Conley BA, Forrest A, Zuhowski EG, Sinibaldi V, Van Echo DA (1987) Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients. Cancer Res 47:6104–6110

    PubMed  Google Scholar 

  • Egorin MJ, Forrest A, Belani CP, Ratain M, Abrams JS Van Echo DA (1989) A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49:3129–3133

    PubMed  Google Scholar 

  • Egorin MJ (1992) Therapeutic drug monitoring and dose optimisation in oncology. In Workman P (ed) New approaches in cancer pharmacology: drug design and development. Springer, Berlin Heidelberg New York, pp 75–91

    Google Scholar 

  • Eichholtz-Wirth H (1980) Dependence of the cytostatic effect of Adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41:886–891

    PubMed  Google Scholar 

  • Eksorg S (1990) Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 29:339–342

    PubMed  Google Scholar 

  • EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose esclation in phase I clinical trials. Commentary and proposed guidelines. Eur J Clin Oncol 23:1083:1087

    Google Scholar 

  • Evans WE, Relling MV (1989) Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327–336

    PubMed  Google Scholar 

  • Evans WE, Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui CH (1991) Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28:15–21

    Google Scholar 

  • Gibaldi M, Perrier D (1982). In: Pharmacokinetics, 2nd edn. Dekker, New York Basel

    Google Scholar 

  • Goldberg JA, Kerr DJ, Willmott N, McKillop JH, McArdle CS (1988) Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer 57:186–189

    PubMed  Google Scholar 

  • Grochow LB, Colvin M (1979) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4:380–394

    PubMed  Google Scholar 

  • Hamilton SF, Evans WE (1981) Accuracy of using pre- and post-dose gentamycin serum concentrations to estimate pharmacokinetics parameters and adjust doses in children and adolescents. Ther Drug Monit 3:57–61

    PubMed  Google Scholar 

  • Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT, Jakobsen A (1991) Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 28:63–68

    PubMed  Google Scholar 

  • Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, Gomis P, Barbaut X, Tahani B (1993) Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting and adaptive control. Ther Drug Monit 15:380–393

    PubMed  Google Scholar 

  • Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528

    PubMed  Google Scholar 

  • Joel SP, Heap L, Robbins S, Clarke PI, Slevin ML (1990) A limited sampling strategy for the calculation of etoposide pharmacokinetics. Proc Am Assoc Clin Oncol 9:67

    Google Scholar 

  • Koup JR, Sack CM, Smith AL, Gibaldi M (1979) Hypothesis for the individualisation of drug dosage. Clin Pharmacokinet 4:460–9

    PubMed  Google Scholar 

  • LaRocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE (1990) Suramin-induced polyneuropathy. Neurology 40:954–960

    PubMed  Google Scholar 

  • Launay MC, Milano G, Iliadis A, Frenay M, Namer N (1989) Limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br J Cancer 60:89–92

    PubMed  Google Scholar 

  • Liliemark J, Peterson C (1991) Pharmacokinetic optimisation of anti-cancer therapy. Clin Pharmacokinet 21:213–231

    PubMed  Google Scholar 

  • Maes RAA, Oellerich M (1988) In: Tobramycin profile. Report IX of the Senate Commission for Clinical-Toxological Analysis, DFG. VCH Verlagsgesellschaft, Weinheim, pp 1–30

    Google Scholar 

  • Mick R, Ratain MJ (1991) Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 83:1560–1564

    PubMed  Google Scholar 

  • Miller AA, Tolley EA, Niell HB, Stewart CF, Griffin JP (1992) Pharmacokinetics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 31:161–166

    PubMed  Google Scholar 

  • Moore MJ, Erlichman C (1987) Therapeutic drug monitoring in oncology: problems and potential in antineoplastic therapy. Clin Pharmacokinet 13:205–227

    PubMed  Google Scholar 

  • Moore MJ, Bunting P, Yuan S, Thiessen JJ (1993) Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit 15:394–399

    PubMed  Google Scholar 

  • Port RE, Edler L, Herrman R, Feldmann U (1991) Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve. Ther Drug Monit 13:96–102

    PubMed  Google Scholar 

  • Ratain MJ, Staubus AE, Schilsky RL, Malspeis L (1988) Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 48:4127–4130

    PubMed  Google Scholar 

  • Ratain MJ, Vogelzang NJ (1987) Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep 71:935–939

    PubMed  Google Scholar 

  • Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner (1989) Adaptive control of etoposide dosing: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45:226–233

    PubMed  Google Scholar 

  • Ratain MJ, Schilsky RL, Conley BA, Egorin MJ (1990) Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739–1753

    PubMed  Google Scholar 

  • Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F (1991a) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9:1480–1486

    PubMed  Google Scholar 

  • Ratain MJ, Robert J, Vijgh WJF van der (1991b) Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 9:871–6

    PubMed  Google Scholar 

  • Robert J (1993) Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines. Cancer Chemother Pharmacol 32:99–102

    PubMed  Google Scholar 

  • Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287–290

    PubMed  Google Scholar 

  • Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A (1992) Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52:64–70

    PubMed  Google Scholar 

  • Schumacher GE (1985) Choosing optimal sampling times for therapeutic drug monitoring. Clin Pharmacol 4:84–92

    Google Scholar 

  • Scheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmacol 9:503–512

    Google Scholar 

  • Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324–327

    PubMed  Google Scholar 

  • Spector R, Park GD, Johnson GF, Vesell ES (1988) Therapeutic drug monitoring. Clin Pharmacol Ther 43:345–353

    PubMed  Google Scholar 

  • Stewart CF, Arbuck SG, Fleming RA, Evans WE (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50:385–393

    PubMed  Google Scholar 

  • Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630–634

    PubMed  Google Scholar 

  • Strömgren A, Sørensen BT, Jakobsen A (1993) A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 32:226–230

    PubMed  Google Scholar 

  • Sulkes A, Collins JM (1987) Reapraisal of some dosage adjustment guidelines Cancer Treat Rep 71:229–33

    PubMed  Google Scholar 

  • Thomson AH, Whiting B (1992) Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 22:447–467

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, NL-1066 EC, Amsterdam, The Netherlands

    L. J. C. van Warmerdam & J. H. Beijnen

  2. Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX, Amsterdam, The Netherlands

    L. J. C. van Warmerdam, W. W. ten Bokkel Huinink & J. H. Beijnen

  3. Department of Pharmaceutical Analysis and Toxicology, Faculty of Pharmacy, State University of Utrecht, P. O. Box 80.082, NL-3508 TB, Utrecht, The Netherlands

    R. A. A. Maes

Authors
  1. L. J. C. van Warmerdam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. W. ten Bokkel Huinink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. A. A. Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Warmerdam, L.J.C., ten Bokkel Huinink, W.W., Maes, R.A.A. et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120, 427–433 (1994). https://doi.org/10.1007/BF01240143

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01240143

Key words

Search

Navigation